Eli Lilly and Company
LLY
NYSE
12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Revenue | 9.35B | 9.50B | 8.31B | 6.96B | 7.30B |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 9.35B | 9.50B | 8.31B | 6.96B | 7.30B |
Cost of Revenue | 1.79B | 1.86B | 1.81B | 1.63B | 1.55B |
Gross Profit | 7.57B | 7.64B | 6.50B | 5.33B | 5.75B |
SG&A Expenses | 1.81B | 1.69B | 1.81B | 1.63B | 1.55B |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 6.16B | 5.96B | 5.97B | 5.25B | 5.09B |
Operating Income | 3.19B | 3.54B | 2.34B | 1.71B | 2.21B |
Income Before Tax | 2.51B | 427.20M | 2.09B | 1.53B | 2.10B |
Income Tax Expenses | 319.10M | 484.60M | 325.70M | 184.80M | 158.70M |
Earnings from Continuing Operations | 2.19B | -57.40M | 1.76B | 1.34B | 1.94B |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 2.19B | -57.40M | 1.76B | 1.34B | 1.94B |
EBIT | 3.19B | 3.54B | 2.34B | 1.71B | 2.21B |
EBITDA | 3.58B | 3.95B | 2.70B | 2.08B | 2.58B |
EPS Basic | 2.42 | -0.06 | 1.96 | 1.49 | 2.14 |
Normalized Basic EPS | 2.13 | 2.41 | 1.56 | 1.14 | 1.46 |
EPS Diluted | 2.42 | -0.06 | 1.95 | 1.49 | 2.14 |
Normalized Diluted EPS | 2.13 | 2.41 | 1.56 | 1.14 | 1.46 |
Average Basic Shares Outstanding | 903.98M | 899.80M | 899.70M | 901.00M | 904.73M |
Average Diluted Shares Outstanding | 903.98M | 899.80M | 902.70M | 903.30M | 904.73M |
Dividend Per Share | 1.13 | 1.13 | 1.13 | 1.13 | 0.98 |
Payout Ratio | 46.49% | -1,770.38% | 57.72% | 75.63% | 45.64% |